A preliminary study on the medical expenditure of Chinese medicine and integrative medicine treatment for influenza a (H1N1) in the fever clinics

Lu, Chuanjian; Luo, Yang; Zhou, Hong; Qin, Xiaolan; Chen, Bojun; Tang, Xue-chun; Deng, Hua; Liang, Zhaohui; Ou, Aihua

doi:10.1007/s11655-010-0563-4

Cited by 9 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TCM therapy was also recommended as a second-line treatment for H7N9 infection. Previous studies have demonstrated that TCMs may have beneficial effects on patients with avian influenza [11,12]. Our univariate logistic regression analysis indicated that the duration of TCM therapy could be partially associated with the prognosis in H7N9-infected patients.…”

Section: Discussionmentioning

confidence: 54%

Clinical Features and Factors Associated with Outcomes of Patients Infected with a Novel Influenza A (H7N9) Virus: A Preliminary Study

Chen

Yang

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

ObjectiveThe present study aimed to analyze clinical features and factors associated with treatment outcomes of H7N9 influenza A virus infection.MethodsThe clinical progress in 18 H7N9-infected patients was monitored and recorded. The clinical features of H7N9 infection were noted and factors associated with treatment outcomes were analyzed by univariate analyses.ResultsThe average ages of patients in recovered and critical conditions were 67.0±10.83 years and 72.75±12.0 years, respectively. Renal insufficiency developed more frequently in critically ill patients (P = 0.023). The duration of traditional Chinese medicine (TCM) therapy was longer in recovered patients than in critically ill patients (P = 0.01). Laboratory tests showed that levels of C-reactive protein, serum creatinine, and myoglobin were significantly higher in critically ill patients than in recovered patients (P = 0.011, 0.04, and 0.016, respectively). Meanwhile, levels of all T cell subsets examined including total CD3+, CD4+, CD8+, and CD45+ T cells were lower in critically ill patients than in recovered patients (P = 0.033, 0.059, 0.015, and 0.039, respectively). Logistic regression analysis demonstrated that C-reactive protein level, myoglobin level and TCM therapy duration were likely associated with treatment outcomes of H7N9 infection (P = 0.032, 0.041 and 0.017, respectively).ConclusionElderly people may have increased risk for H7N9 virus infection. T cell-mediated responses play an important role in defense against the H7N9 virus. C-reactive protein level, myoglobin level and TCM duration may be associated with treatment outcomes of H7N9 infection.

show abstract

Section: Discussionmentioning

confidence: 54%

Clinical Features and Factors Associated with Outcomes of Patients Infected with a Novel Influenza A (H7N9) Virus: A Preliminary Study

Chen

Yang

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Interestingly, while some cellular consequences of TREM-1 activation such as upregulation of chemokines, cytokines, matrix metalloproteases, and post transcriptional gene silencing (PTGS)/COX2 are similar to those observed upon lipopolysaccharide stimulation, which is consistent with a core inflammatory response, other immunomodulatory factors, including secreted phosphoprotein 1 (SPP1) and M-CSF, are induced selectively in response to TREM-1 cross-linking [38]. In line with these findings, inhibition of TREM-1 in vivo was shown to reduce release of MCP-1, TNFα, IL-1β, IL-6, and M-CSF [28,36,40–44]. Blockade of TREM-1 is a promising approach in a variety of inflammation-associated disorders including sepsis, cancer, rheumatoid arthritis and other serious diseases with unmet clinical needs [28,36,39–41,43–46].…”

Section: Introductionmentioning

confidence: 74%

Blockade of TREM-1 prevents vitreoretinal neovascularization in mice with oxygen-induced retinopathy

Rojas

Caldwell

Sigalov

2018

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

View full text Add to dashboard Cite

In pathological retinal neovascularization (RNV) disorders, the retina is infiltrated by activated leukocytes and macrophages. Triggering receptor expressed on myeloid cells 1 (TREM-1), an inflammation amplifier, activates monocytes and macrophages and plays an important role in cancer, autoimmune and other inflammation-associated disorders. Hypoxia-inducible TREM-1 is involved in cancer angiogenesis but its role in RNV remains unclear. Here, to close this gap, we evaluated the role of TREM-1 in RNV using a mouse model of oxygen-induced retinopathy (OIR). We found that hypoxia induced overexpression of TREM-1 in the OIR retinas compared to that of the room air group. TREM-1 was observed specifically in areas of pathological RNV, largely colocalizing with macrophage colony-stimulating factor (M-CSF) and CD45- and Iba-1-positive cells. TREM-1 blockade using systemically administered first-in-class ligand-independent TREM-1 inhibitory peptides rationally designed using the signaling chain homooligomerization (SCHOOL) strategy significantly (up to 95%) reduced vitreoretinal neovascularization. The peptides were well-tolerated when formulated into lipopeptide complexes for peptide half-life extension and targeted delivery. TREM-1 inhibition substantially downregulated retinal protein levels of TREM-1 and M-CSF suggesting that TREM-1-dependent suppression of pathological angiogenesis involves M-CSF. Targeting TREM-1 using TREM-1-specific SCHOOL peptide inhibitors represents a novel strategy to treat retinal diseases that are accompanied by neovascularization including retinopathy of prematurity.

show abstract

“…All the studies were conducted in the general population. Research was conducted on hand hygiene [107], [108], infection control [109], facemask use [108], [110], school closure [111], [112], physical exercise [113], alternative therapies including tea catechin [114], passive immunotherapy for management of severe cases of influenza infection [115] and use of traditional medicine [116]. One modelling study assessed methods to improve the effectiveness of different antiviral strategies [117], and another evaluated combinations of methods including enhanced surveillance with isolation, segregation and personal protective equipment to limit influenza transmission in closed environments [118].…”

Section: Resultsmentioning

confidence: 99%

A Review of the Evidence to Support Influenza Vaccine Introduction in Countries and Areas of WHO's Western Pacific Region

2013

View full text Add to dashboard Cite

BackgroundImmunization against influenza is considered an essential public health intervention to control both seasonal epidemics and pandemic influenza. According to the World Health Organization (WHO), there are five key policy and three key programmatic issues that decision-makers should consider before introducing a vaccine. These are (a) public health priority, (b) disease burden, (c) efficacy, quality and safety of the vaccine, (d) other inventions, (e) economic and financial issues, (f) vaccine presentation, (g) supply availability and (h) programmatic strength. We analyzed the body of evidence currently available on these eight issues in the WHO Western Pacific Region.Methodology/Principal FindingsStudies indexed in PubMed and published in English between 1 January 2000 and 31 December 2010 from the 37 countries and areas of the Western Pacific Region were screened for keywords pertaining to the five policy and three programmatic issues. Studies were grouped according to country income level and vaccine target group. There were 133 articles that met the selection criteria, with most (90%) coming from high-income countries. Disease burden (n = 34), vaccine efficacy, quality and safety (n = 27) and public health priority (n = 27) were most frequently addressed by studies conducted in the Region. Many studies assessed influenza vaccine policy and programmatic issues in the general population (42%), in the elderly (24%) and in children (17%). Few studies (2%) addressed the eight issues relating to pregnant women.Conclusions/SignificanceThe evidence for vaccine introduction in countries and areas in this Region remains limited, particularly in low- and middle-income countries that do not currently have influenza vaccination programmes. Surveillance activities and specialized studies can be used to assess the eight issues including disease burden among vaccine target groups and the cost-effectiveness of influenza vaccine. Multi-country studies should be considered to maximize resource utilization for cross-cutting issues such as vaccine presentation and other inventions.

show abstract

A preliminary study on the medical expenditure of Chinese medicine and integrative medicine treatment for influenza a (H1N1) in the fever clinics

Cited by 9 publications

References 6 publications

Clinical Features and Factors Associated with Outcomes of Patients Infected with a Novel Influenza A (H7N9) Virus: A Preliminary Study

Clinical Features and Factors Associated with Outcomes of Patients Infected with a Novel Influenza A (H7N9) Virus: A Preliminary Study

Blockade of TREM-1 prevents vitreoretinal neovascularization in mice with oxygen-induced retinopathy

A Review of the Evidence to Support Influenza Vaccine Introduction in Countries and Areas of WHO's Western Pacific Region

Contact Info

Product

Resources

About